Dhar K K, Branigan K, Parkes J, Howells R E, Hand P, Musgrove C, Strange R C, Fryer A A, Redman C W, Hoban P R
Centre for Cell and Molecular Medicine, University of Keele School of Postgraduate Medicine, North Staffordshire Hospital, Stoke-on-Trent, UK.
Br J Cancer. 1999 Dec;81(7):1174-81. doi: 10.1038/sj.bjc.6690826.
The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4-19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCND1 was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both cytoplasmic and nuclear protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification.
采用免疫组织化学方法分析了81例上皮性卵巢癌患者肿瘤切片中细胞周期蛋白D1蛋白的表达情况。肿瘤中超过10%的肿瘤细胞过表达细胞周期蛋白D1被视为阳性。因此,在所检测的81例病例中,有72例(89%)观察到细胞周期蛋白D1过表达。在24/81(30%)的肿瘤中,蛋白在细胞核和细胞质中均有检测到,在48/81(59%)的肿瘤中仅定位于细胞质。细胞周期蛋白D1在交界性肿瘤和浸润性肿瘤中均有过表达。蛋白过表达与肿瘤分期及分化之间无关联。此外,未观察到细胞周期蛋白D1表达与临床结局之间的相关性。然而,在过表达细胞周期蛋白D1的肿瘤(n = 72)中,浆液性组织学类型的肿瘤中蛋白仅定位于细胞质的比例高于非浆液性组织学类型的肿瘤(P = 0.004,优势比4.8,95%置信区间1.4 - 19.1)。使用针对细胞周期蛋白D1的单克隆抗体进行的蛋白质印迹分析在7个仅显示细胞质免疫染色的肿瘤匀浆和1个显示细胞核和细胞质免疫染色的肿瘤匀浆中鉴定出一种36 kDa的蛋白。使用限制性片段长度多态性聚合酶链反应和聚合酶链反应多重分析,在29个显示细胞周期蛋白D1蛋白过表达的肿瘤中有1个检测到细胞周期蛋白D1基因(CCND1)的扩增。我们得出结论,CCND1表达失调导致细胞质和细胞核蛋白定位,这在卵巢癌中是常见事件,且主要发生在无基因扩增的情况下。